Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Sponsor: Umoja Biopharma
Summary
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
Official title: A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed/Refractory (R/R) CD19+ B-cell Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
106
Start Date
2025-03-10
Completion Date
2029-03
Last Updated
2026-01-12
Healthy Volunteers
No
Conditions
Interventions
UB-VV111
UB-VV111 is a gene therapy that generates CD19 CAR T cells in the body.
rapamycin
Rapamycin is an FDA-approved drug.
Locations (8)
City of Hope
Duarte, California, United States
The David and Etta Jonas Center for Cellular Therapy
Chicago, Illinois, United States
Washington University School of Medicine/Siteman Cancer Center
St Louis, Missouri, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
University of Cincinnatti Medical Center
Cincinnati, Ohio, United States
Fred Hutch Cancer Center
Seattle, Washington, United States
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
St. Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia